Pelvic lymph node dissection in patients treated for testis cancer: The Memorial Sloan Kettering Cancer Center experience Journal Article


Authors: Alanee, S. R.; Carver, B. S.; Feldman, D. R.; Motzer, R. J.; Bosl, G. J.; Sheinfeld, J.
Article Title: Pelvic lymph node dissection in patients treated for testis cancer: The Memorial Sloan Kettering Cancer Center experience
Abstract: Objective To describe the pathologic findings and clinical outcome data for patients undergoing pelvic lymph node dissection (PLND) in the course of management of testicular germ cell tumors at Memorial Sloan Kettering Cancer Center (MSKCC). Patients and Methods Following institutional review board approval, data on 2186 patients who underwent retroperitoneal lymph node dissection (RPLND) at MSKCC between 1989 and 2011 were retrospectively reviewed. Of these 2186 patients, we analyzed data for 44 patients (2%) who underwent PLND at the time of RPLND. Results PLND was performed in 14/44 (31%) patients at time of primary RPLND (P-RPLND), and in 21/44(48%) patients at time of postchemotherapy RPLND (PC-RPLND), usually for suspicious radiologic or intraoperative findings, whereas 9/44 (21%) underwent PLND for treatment of relapse. Positive pelvic findings on imaging included pelvic disease ≤5 cm in 17/44 (39%) patients and >5 cm in 11/44 (25%) patients (median size = 4 cm). At the time of PC-RPLND, alpha-fetoprotein and beta human chorionic gonadotropin were elevated in 6/21 (29%) and 4/21 (19%) patients, respectively. Histology revealed teratoma in 15/44 (34%) and viable tumor in 5/44 (11%) patients. At a median follow-up of 46 months, 40/44 (91%) patients were living without disease, 3/44 (7%) were living with disease (1 after PC-RPLND and 2 after relapse), and 1/44 (2%) died of other causes. Conclusion PLND was performed infrequently in our series of patients who underwent RPLND for testis cancer. Teratoma was the dominant tumor histology in the resected tissue © 2016 Elsevier Inc.
Journal Title: Urology
Volume: 95
ISSN: 0090-4295
Publisher: Elsevier Science, Inc.  
Date Published: 2016-09-01
Start Page: 128
End Page: 131
Language: English
DOI: 10.1016/j.urology.2016.05.014
PROVIDER: scopus
PMCID: PMC5012113
PUBMED: 27235751
DOI/URL:
Notes: Article -- Export Date: 2 November 2016 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Robert Motzer
    761 Motzer
  2. Darren Richard Feldman
    172 Feldman
  3. Joel Sheinfeld
    197 Sheinfeld
  4. Brett Stewart Carver
    109 Carver
  5. George Bosl
    261 Bosl